Table I.

Characteristics of Patients

Baseline characteristics of patients, No.	2319
Age, y	67.8±12.0
BMI, kg/m2	23.9±3.6
Men, No. (%)	1271 (54.8)
Comorbidity, No. (%)	1704 (73.5)
Dyslipidemia, No. (%)	566 (24.4)
Ischemic heart disease, No. (%)	435 (18.8)
Diabetes mellitus, No. (%)	353 (15.2)
Cerebral vascular disorder, No. (%)	188 (8.1)
Chronic kidney disease, No. (%)	156 (6.7)
Cilnidipine monotherapy during the study, No. (%)	812 (35.0)
Combination therapy during the study, No. (%)	1507 (65.0)
Concomitant antihypertensive drug
ARB, No. (%)	1082 (46.7)
Diuretic, No. (%)	303 (13.1)
β‐Blocker, No. (%)	195 (8.4)
αβ‐Blocker, No. (%)	176 (7.6)
CCB, No. (%)	171 (7.4)
ACE inhibitor, No. (%)	131 (5.6)
α‐Blocker, No. (%)	61 (2.6)

Abbreviations: ACE, angiotensin‐converting enzyme; ARB, angiotensin receptor blocker; CCB, calcium channel blocker. Age and body mass index (BMI): mean±standard deviation.